Proteros biostructures GmbH, a leading Germany-based contract research organisation focused on early-stage drug discovery, has won a new investor. Private equity firm Inflexion has agreed to acquire a minority share in the company through its Partnership Capital II fund. Proteros founder Torsten Neuefeind will continue to lead the company as CEO and retains the majority shareholding in Proteros. With the support of Inflexion, Proteros aims to scale globally both organically and through acquisitions, particularly in the US.
Hengeler Mueller advised Proteros' majority shareholder on the transaction. The team was led by partner Daniel Möritz (M&A) and included partners Markus Ernst (Tax) (both Munich), Alf-Henrik Bischke (Antitrust, Düsseldorf), Hendrik Bockenheimer (Employment, Frankfurt) and Wolfgang Kellenter (IP/IT, Düsseldorf), counsel Anja Balitzki (Antitrust) and Matthias Rothkopf (IP/IT) (both Düsseldorf) as well as associates Lisa Schwarz, Maximilian Mayer, Michael Mertel (all M&A), Tim Würstlin, Isabella Zimmerl (both Tax) (all Munich), Jan Schülting (FDI, Düsseldorf), Susanne Walzer (Employment, Frankfurt) and Johannes Jäkle (IP/IT, Düsseldorf).